Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of “Moderate Buy” from Analysts

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $19.00.

A number of research firms have weighed in on CTNM. Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Wednesday, January 21st. Leerink Partners started coverage on shares of Contineum Therapeutics in a research note on Thursday, November 13th. They set an “outperform” rating and a $22.00 price target on the stock. Robert W. Baird reduced their price target on shares of Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Monday, November 24th. Morgan Stanley restated an “equal weight” rating and issued a $14.00 price objective (down previously from $23.00) on shares of Contineum Therapeutics in a research note on Thursday, January 8th. Finally, Royal Bank Of Canada dropped their price objective on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating on the stock in a report on Friday, November 21st.

Contineum Therapeutics Stock Performance

NASDAQ:CTNM opened at $14.26 on Friday. Contineum Therapeutics has a 1 year low of $3.35 and a 1 year high of $14.94. The stock has a market cap of $416.11 million, a P/E ratio of -6.34 and a beta of 1.21. The stock has a 50-day simple moving average of $11.65 and a 200-day simple moving average of $10.43.

Contineum Therapeutics (NASDAQ:CTNM) last posted its earnings results on Thursday, October 30th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.13. On average, equities research analysts predict that Contineum Therapeutics will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Contineum Therapeutics in the first quarter valued at approximately $118,000. Strs Ohio purchased a new stake in Contineum Therapeutics in the 1st quarter valued at $27,000. Y Intercept Hong Kong Ltd purchased a new stake in Contineum Therapeutics in the 2nd quarter valued at $140,000. Monaco Asset Management SAM acquired a new stake in Contineum Therapeutics during the 2nd quarter worth $298,000. Finally, Franklin Resources Inc. boosted its stake in Contineum Therapeutics by 7.8% during the 2nd quarter. Franklin Resources Inc. now owns 1,698,825 shares of the company’s stock worth $6,744,000 after purchasing an additional 122,644 shares during the period.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.